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Abstract
Background: The aim of this study was to determine and compare patients' and physicians'
perceptions of benefits and risks of long term benzodiazepine use for insomnia in the elderly.
Methods: A cross-sectional study (written survey) was conducted in an academic primary care
group practice in Toronto, Canada. The participants were 93 patients over 60 years of age using a
benzodiazepine for insomnia and 25 physicians comprising sleep specialists, family physicians, and
family medicine residents. The main outcome measure was perception of benefit and risk scores
calculated from the mean of responses (on a Likert scale of 1 to 5) to various items on the survey.
Results: The mean perception of benefit score was significantly higher in patients than physicians
(3.85 vs. 2.84, p < 0.001, 95% CI 0.69, 1.32). The mean perception of risk score was significantly
lower in patients than physicians (2.21 vs. 3.63, p < 0.001, 95% CI 1.07, 1.77).
Conclusions: There is a significant discordance between older patients and their physicians
regarding the perceptions of benefits and risks of using benzodiazepines for insomnia on a long term
basis. The challenge is to openly discuss these perceptions in the context of the available evidence
to make collaborative and informed decisions.
Background
Many older people suffer from insomnia and are com-
monly prescribed benzodiazepines for symptomatic man-
agement. Among adults aged 65 and older who live in the
community, up to 42% reported difficulty falling asleep
or staying asleep [1]. The prevalence of benzodiazepine
prescriptions in older people is also high: 22.5% of people
aged 65 and older in Ontario, Canada reported use of
benzodiazepines [2]. Furthermore, older people are more
likely to continue using these medications for extended
periods once they are prescribed them [3].
The research available on the benefits and risks of benzo-
diazepine use for insomnia in older people is surprisingly
deficient for the magnitude of this issue. Notably, there
are no prospective studies that have looked at the efficacy
of benzodiazepine use for insomnia for a duration of
greater than one month [4]. Over the short term, meta-
analyses show a mild to moderate treatment effect in
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quantitative and subjective measures of sleep [5,6]. How-
ever, in practice, patients may be taking these medications
for over a year or more.
There are concerns about prescribing benzodiazepines be-
cause of potential adverse effects. However, there are no
studies that clearly demonstrate adverse effects due to
long term use of short acting benzodiazepines in older
populations for insomnia. The evidence that does exist is
limited by small sample sizes, short durations, or not ad-
dressing the population of interest, namely community-
dwelling patients aged sixty and over. Benzodiazepines
have been associated with increased risk in hip fractures
[7–9], motor vehicle crashes [10], and cognitive impair-
ment [11]. The significance of these associations is un-
clear. While some studies have shown increased risks in
long acting benzodiazepines, higher doses, or longer du-
rations of therapy, others have shown none. Addiction
and dose escalation are also widespread concerns, despite
no long term studies to validate them. Similarly, the ad-
verse effects of benzodiazipine withdrawl in older patients
using benzodiazepines for insomnia are unclear. What is
clear is that there is no consensus on the overall risks of
benzodiazepine use for insomnia in older persons as the
evidence to date is either inconclusive, conflicting, or an-
ecdotal.
With the paucity of clinically relevant and long term re-
search in older populations, physicians lack evidence-
based guidelines on how to advise long term users of ben-
zodiazepines. Yet the common dilemma arises when an
older patient requests the renewal of the benzodiazepine
from a physician who has reservations due to the per-
ceived risks. This study sought to quantify this potential
discordance between patients and physicians with regard
to long term benzodiazepine use for insomnia.
Methods
The subjects in the patient group were recruited from the
practices of thirteen family physicians in an academic
family practice in Toronto, Canada. By reviewing tele-
phone records, patients who renewed a prescription for a
benzodiazepine from January to June 2001 were identi-
fied as potential subjects. Patients 60 years and older and
receiving benzodiazepine prescriptions for greater than
one year duration were included. The list of subjects was
then reviewed by their respective family doctors. The phy-
sician could veto sending a survey to a patient for various
reasons such as undue psychological distress of receiving
the survey, inability to complete the form due to physical
or cognitive impairment, or because the patient was not
using the medication for insomnia.
The physician group sample consisted of all staff and res-
ident physicians at the academic family practice. It also in-
cluded the sleep specialists in three academic teaching
hospitals affiliated with the University of Toronto.
The survey was pretested among a small sample of physi-
cans and patients (n = 6) to ensure clarity of wording. Sur-
veys were mailed out to all eligible patient and physician
subjects. A follow-up mailing was conducted one month
after the initial one to those who did not respond.
Survey design
Seven items including one for overall opinion were used
to assess the benefits of benzodiazepine use. They were
based on criteria described by Dement which included
sleep latency, night time awakenings, total sleep time, and
feeling of being well-rested on awakening [4]. Improved
daytime function and overall well-being have also been
noted to be important clinical outcomes and were includ-
ed [6]. Regarding the risks, subjects were asked to respond
to nine questions on potential adverse effects of benzodi-
azepine use that have been identified in the literature [5].
These included daytime drowsiness, confusion, cognitive
impairment, concentration problems, dependence, falls,
hip fractures, motor vehicle crashes, and overall assess-
ment of risk.
The patients and physicians were asked the same items re-
garding their perceptions of specific benefits and risks of
benzodiazepine use. While the patients responded based
on their personal experiences, the physicians provided
their perceptions for a hypothetical older person using a
short-acting benzodiazepine on a long term basis. The
survey employed a Likert scale ranging from one to five,
which correlated to strongly disagreeing to strongly agree-
ing to the various statements. Additional information re-
quested from patient subjects included the name of
sleeping medication, frequency and duration of use, other
methods used to help sleep, and comorbid conditions.
Data analysis
The main outcome measures were the mean benefit and
risk scores. A benefit score was calculated for each subject
by taking the mean of all the responses from the questions
on perceived benefits. Likewise, a risk score was calculated
by taking the mean of responses from the questions on
perceived risk. The scores potentially ranged from a mini-
mum of 1 to a maximum of 5 as per the Likert scale. A T-
test for independent samples was conducted to assess sta-
tistical significance between the scores for patients and
physicians.
Ethics
The research ethics board of Sunnybrook and Women's
College Health Sciences Centre in Toronto, Canada ap-
proved the study question and protocol.BMC Family Practice 2002, 3 http://www.biomedcentral.com/1471-2296/3/9
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Results
Two hundred and forty-two potential patient subjects
were initially identified through review of telephone re-
newal records (Figure 1). Of these subjects, 44 were ex-
cluded by the family physician for various reasons, most
commonly for undue anxiety (21) or no longer with prac-
tice due to death or moving (11). One hundred and nine-
ty-eight surveys were mailed out. Five surveys did not
reach their destinations. After two separate mailings, 131
responses were received from patients. Of these, 23 said
they were not currently taking a medication for insomnia.
Another 14 were not using a benzodiazepine, and three
did not specify their medication. Ninety-three returned
surveys from current benzodiazepine users were analyzed.
The response rate was 61% for patient subjects who met
the inclusion criteria.
Thirty-nine potential physician subjects were identified
(11 sleep specialists, 12 family doctors, 16 family medi-
cine residents). Twenty-five surveys were returned. One
survey did not reach its destination. The response rate was
66% for physician subjects.
Table 1 shows demographic characteristics of patients
who responded, did not respond, and those who were in-
itially excluded by their family doctors. There was no sta-
tistically significant difference between the groups. The
average age of responders was 77 years old. The percent-
age of female responders was 67%.
The types of benzodiazepines used by the patient subjects
varied (Table 2). Eleven percent were using a long acting
benzodiazepine such as diazepam, clonazepam or flu-
razepam. Eighty-nine percent were using a short acting
benzodiazepine, the three most common being lo-
razepam, temazepam, and oxazepam.
Figure 1
Recruitment and Response Rate
Subjects identified
242
44 Excluded by their MD’s
198
5 surveys returned to sender
193
Responded to Survey
133
Using a 
Medication
110
Not Using a 
Medication
23*
93 using a benzodiazepine
14* not using a benzodiazepine
  3* did not specify
Return rate =       93          =  61%
                       193 – 40*
*excluded
Table 1: Demographic Characteristics
Characteristics Respondents (n = 93) Non-Respondents (n = 61) Not authorized to receive survey 
(n = 43)
Age Group (%)
60–69 20 18 16
70–79 32 38 30
80–89 42 33 53
90–99 51 1 0
Mean Age (yrs) 77 78 78
Gender (%)
Male 33 26 23
Female 67 74 77BMC Family Practice 2002, 3 http://www.biomedcentral.com/1471-2296/3/9
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Calculated mean benefit and risk scores for patient and
physician groups are shown in Table 3. The mean score for
perceived benefit from benzodiazepines among patients
(3.85) was higher than physicians subjects (2.84). The dif-
ference of 1.01 was statistically significant (p < 0.001)
with a 95% CI of 0.69–1.32. The mean score for perceived
risk among patients (2.21) was lower than that for physi-
cians (3.63). The difference of 1.43 was also significant (p
< 0.001) with a 95% CI of 1.07–1.77.
Discussion
To our knowledge, this study is the first to directly com-
pare the perceived benefits and risks of benzodiazepine
use for insomnia in patients and physicians. It showed a
clear discordance in perceptions. Overall, the patients felt
there was generally good benefit in using benzodi-
azepines on a long term basis for insomnia whereas the
physicians felt the benefits were neutral. With respect to
the risks of using benzodiazepines, the patients generally
felt they were low whereas the physicians felt they were
high.
Is this difference clinically relevant? We think this discord-
ance is of clinical importance because it is likely not ad-
dressed explicitly in the patient encounter. Concordance
is an important clinical issue in primary care. Recent re-
search has demonstrated that misunderstandings between
patients and physicians seem to be associated with pa-
tients' lack of participation and are often based on as-
sumptions about medications that are not made explicit
in the clinical encounter [12]. There is also compelling ev-
idence of a lack of open discourse between patients and
physicians concerning the benefits and risks of prescrip-
tion medication. The resulting discordance can lead to
non-adherence or potentially adverse consequences of
taking a medication. In the area of long term benzodi-
azepine use for insomnia in the patients aged sixty and
over, there is a large gap in perceptions that needs to be
addressed. Recent work in shared decision making pro-
vides a promising avenue of research to redress these gaps
[13].
Part of the reason for the discordance may be the percep-
tions in the medical community towards the risks of ben-
zodiazepines. Due in part to the negative publicity and
perceived high levels of risk, there has been a trend since
the 1970s towards decreased use in benzodiazepines [2].
The increased risks attributed to benzodiazepines have of-
ten been associated with long acting benzodiazepines or
higher doses. Thus, small doses of short acting hypnotics,
most commonly prescribed in this particular family prac-
tice, are generally viewed as safer. Although short acting
benzodiazepines are not without risks in older people, the
fear engendered in using these medications for patients is
not substantiated by the current evidence.
With perceived benefits from patients and no convincing
evidence of adverse outcomes, it can be argued that a long
term use of short acting benzodiazepines may have thera-
peutic value. Should an older individual who is distressed
by insomnia, but consistently responds well to a low-dose
short acting benzodiazepine be denied this medication?
Like all medical decisions, the patient should be made
aware of the benefits and risks in a patient-centred ap-
proach. For benzodiazepines, the potential risks include
possible low level dependence and rebound insomnia on
discontinuation. On the other hand, the potential risks of
not treating persistent insomnia can also be significant
[14]. They may include poor daytime functioning, de-
creased mood, and decreased sense of well being. Deci-
sions about using benzodiazepines for insomnia can be
complex, and many factors in the patient's context should
be considered.
Alternatives
There is a growing amount of research available on alter-
natives to benzodiazepines for insomnia. Non-prescrip-
Table 2: Benzodiazepines Used by Patient Subjects
Medication No. of Patients
Long Elimination Half Life (11%)
Diazepam 5
Clonazepam 4
Flurazepam 1
Short Elimination Half Life (89%)
Lorazepam 60
Temazepam 15
Oxazepam 4
Triazolam 3
Lectopam 1
Table 3: Mean Benefit and Risk Scores – Patients vs. Physicians
Patients 
(n = 93)
Physicians 
(n = 25)
Difference
Mean Benefit 
Score
3.84 2.84 1.00 (0.69–1.32) p 
< 0.001
Mean Risk 
Score
3.63 2.21 1.42 (1.07–1.77) p 
< 0.001BMC Family Practice 2002, 3 http://www.biomedcentral.com/1471-2296/3/9
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tion sleep products [15] and newer short acting non-
benzodiazepine medications such as zopiclone (Im-
ovane®) and zaleplon (Starnoc®) are increasingly used by
patients. Their role versus traditional benzodiazepines
with respect to efficacy or harm has yet to be demonstrat-
ed [16]. Furthermore, cognitive behavioural therapy
(CBT) [17,18] shows promising results of long term sleep
improvements, and would be a non-pharmacologic con-
sideration where available.
Limitations
There are a number of limitations to this survey. First, the
sample for this survey was non-random and taken from a
single academic family practice. Although there is no ap-
parent reason to believe that these patients would respond
differently to others in the community at large, generaliz-
ability is a potential issue. Second, the possibility of re-
sponse bias may come from potential difficulties for some
patients to complete the survey due to decreased cognitive
or physical ability. Additionally, there is a possibility that
respondants believed that a less than favourable account
of their medication could result in its withdrawal. Finally,
the goal of the survey was to quantify whether a discrep-
ancy in the perceptions between patients and physicians
existed. The reasons for this phenomenon were not ex-
plored. Further research in the form of in-depth qualita-
tive studies with patients and physicians is required to
further understand the reasons for this discordance.
Conclusions
There is a significant discordance between patients aged
sixty and over and their physicians regarding the percep-
tions of risks and benefits of using short acting benzodi-
azepines for insomnia on a long term basis. Patients feel
that benzodiazepines are more effective than the physi-
cians that prescribe them. Physicians have traditionally
been taught that benzodiazepines are generally risky and
perhaps dangerous in the patients aged sixty and over.
This perception is not shared by the patients, nor support-
ed by the literature for short acting benzodiazepines.
When approaching insomnia in patients aged sixty and
over, ruling out underlying medical and psychological
disorders, medication causes, and environmental factors
contributing to insomnia continues to be essential. Pa-
tients should also be aware of proper sleep hygiene and
non-pharmacologic methods to treat insomnia that dem-
onstrate evidence of being efficacious. Regarding benzodi-
azepine use in the patients aged sixty and over for
insomnia, the evidence for safe and effective long term use
is lacking. Thus there is an increased need for patients and
physicians to openly discuss their perceptions with the
available evidence to make collaborative and informed
decisions. Recent research in shared decision making be-
tween physicians and patients points out promising direc-
tions for this possibility.
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